rs17728338 — TNIP1 TNIP1/ABIN1 variant

Intergenic regulatory variant near TNIP1 whose A allele reduces ABIN1-mediated NF-kB braking, conferring OR=1.69 for psoriasis per allele and substantially elevated generalized pustular psoriasis risk in homozygous carriers

See your personal result for TNIP1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TNIP1 — The Second Brake in the NF-kB Circuit

The immune system's inflammatory response is governed by a finely tuned off-switch. NF-kB, the master transcription factor driving cytokine production and immune cell activation, must be rapidly shut off once a threat has passed. The primary brake is A20 (encoded by TNFAIP3), a deubiquitinase that strips activating ubiquitin chains from signaling intermediates. But A20 cannot operate alone — it requires a scaffolding partner to localize to the correct intracellular compartment and engage its substrates. That partner is ABIN-111 ABIN-1
A20-Binding Inhibitor of NF-kB 1, encoded by TNIP1 (TNF alpha-induced protein 3-interacting protein 1).

rs17728338 is an intergenic SNP located near the TNIP1 gene on chromosome 5 that was identified in the landmark 2009 psoriasis genome-wide association study22 2009 psoriasis genome-wide association study
Nair et al. analyzed 1,409 cases and 1,436 controls in discovery, followed by 5,048 cases and 5,041 controls in validation; published Nature Genetics February 2009 alongside TNFAIP3 as one of seven psoriasis susceptibility loci. The A risk allele carries an odds ratio of approximately 1.69 per allele for psoriasis — among the largest effect sizes of any common psoriasis SNP outside the HLA region — and extends to psoriatic arthritis and, in homozygous carriers, to a dramatically elevated risk of generalized pustular psoriasis.

The Mechanism

TNIP1 encodes ABIN-1, a protein that binds A20 directly through its AHD2 (ABIN homology domain 2) and also binds polyubiquitin chains via its UBAN (ubiquitin-binding domain in ABIN proteins) domain. This dual binding positions ABIN-1 as the bridge that delivers A20 to its ubiquitinated substrates (RIPK1, TRAF6, NEMO) within the NF-kB signaling complex. When ABIN-1 is absent or reduced, A20 enzymatic activity cannot be targeted appropriately, and NF-kB termination is impaired even if A20 protein levels are normal.

rs17728338 sits in the intergenic region near TNIP1 and does not alter the ABIN-1 protein sequence. Its biological effect is regulatory: the A allele is associated with reduced TNIP1 expression in immune cells and keratinocytes, meaning less ABIN-1 protein is available to scaffold A20. The consequence is attenuated NF-kB termination after inflammatory stimuli — NF-kB-driven cytokines (TNF-α, IL-1β, IL-6, IL-8) are produced in greater quantity and for longer after each immune trigger. In skin, this excess NF-kB tone drives the Th17/IL-23 inflammatory axis that underlies psoriatic plaques33 psoriatic plaques
Psoriatic plaques form when keratinocytes proliferate excessively and immune cells infiltrate the dermis; both processes are driven by NF-kB-dependent cytokines.

Critically, the TNIP1-TNFAIP3 axis functions as a two-component brake: A20 provides the enzymatic cutting activity; ABIN-1 provides the targeting scaffold. Impairing either component degrades the entire system. The rs610604 variant in TNFAIP3 (already in this database) affects the A20 side; rs17728338 affects the ABIN-1 side. Carriers of risk alleles at both loci face compounded NF-kB dysregulation.

The Evidence

The psoriasis association has been replicated across multiple ancestries. A meta-analysis of 13 case-control studies44 meta-analysis of 13 case-control studies
Gong et al. 2020, BMC Medical Genetics; 13,908 psoriasis cases and 20,051 controls across European, Chinese, South Asian, and other populations confirmed A vs G OR=1.69 (95% CI 1.58–1.80, P<0.00001) using a fixed-effect model — the most precise estimate available. Fine-mapping of eight psoriasis susceptibility loci55 Fine-mapping of eight psoriasis susceptibility loci
Das et al. 2015, European Journal of Human Genetics; 2,699 cases and 2,107 European controls with custom genotyping and imputation confirmed rs17728338 as the single independent signal at the TNIP1 locus (P=4.15×10⁻¹³), establishing it as the primary functional tag SNP rather than a proxy for another causal variant.

The association extends to psoriatic arthritis66 psoriatic arthritis
PsA is the inflammatory arthritis affecting approximately 30% of people with psoriasis, causing joint damage and disability. Bowes et al. confirmed rs17728338 as a PsA susceptibility locus (P=3.5×10⁻⁵) in a UK multi-center study; Yang et al. demonstrated an even stronger PsA-specific effect in Chinese Han patients (P=2.20×10⁻⁸ for PsA vs. P=1.21×10⁻⁴ for psoriasis vulgaris), suggesting ABIN-1 may be particularly important in the joint inflammatory compartment.

At the severe end of the spectrum, TNIP1 variants including rs17728338 are associated with generalized pustular psoriasis77 generalized pustular psoriasis
GPP is a life-threatening form of psoriasis involving widespread pustules, fever, and systemic inflammation; distinct from plaque psoriasis pathogenically. The TNIP1 haplotype carrying rs17728338 A allele showed OR=4.16 (P=4.46×10⁻⁷) in a Chinese Han GPP cohort, with substantially elevated frequency in GPP cases versus controls. Homozygous AA carriers, who lack both copies of the protective G allele, show particularly marked GPP susceptibility under recessive models in published literature — the biological plausibility being that complete ABIN-1 scaffold deficiency allows essentially unregulated NF-kB signaling in triggered skin.

A notable counter-finding: the A allele that increases psoriasis risk simultaneously decreases atopic dermatitis risk88 decreases atopic dermatitis risk
Baurecht et al. 2015, AJHG, identified pleiotropic alleles at TNIP1 with opposing effects across psoriasis and atopic dermatitis in over 19,000 individuals. Psoriasis and atopic dermatitis occupy opposite ends of the Th1/Th2 immune spectrum; variants that amplify NF-kB/Th1/Th17 signaling (psoriasis) often suppress the Th2 axis (atopic dermatitis). The A allele here is protective against atopic dermatitis — reinforcing that rs17728338 specifically tags NF-kB/Th17 inflammatory capacity rather than generalized immune activation.

Practical Actions

For AG and GG heterozygous carriers, the primary risk is for plaque psoriasis and psoriatic arthritis. Because TNIP1 impairment affects NF-kB-driven inflammation in skin and joints, the most evidence-based interventions target NF-kB pathway activity. The VITAL randomized trial99 VITAL randomized trial
25,871 participants randomized to vitamin D3 2,000 IU/day, omega-3 1g/day, both, or placebo over 5 years demonstrated that vitamin D3 reduces incident autoimmune disease by 22% (HR=0.78, P=0.05) — the largest randomized evidence for a nutritional intervention targeting NF-kB-mediated autoimmunity. Maintaining serum 25(OH)D above 40 ng/mL also supports keratinocyte differentiation directly, reducing psoriatic hyperproliferation independent of its immunological effects.

For AA homozygous carriers, the clinical concern extends beyond plaque psoriasis to pustular disease. Any new-onset widespread pustular eruption with fever warrants immediate emergency evaluation — GPP can progress to sepsis and multi-organ failure. Early rheumatological and dermatological assessment is warranted given the elevated joint involvement risk.

Interactions

rs17728338 and rs610604 (TNFAIP3) represent the two sides of the same NF-kB brake: ABIN-1 (TNIP1) scaffolds A20 (TNFAIP3) to its ubiquitinated substrates. Carrying risk alleles at both loci impairs both the targeting (ABIN-1) and enzymatic (A20) functions of the NF-kB termination complex simultaneously. Carriers of both risk alleles are candidates for a compound action assessing combined NF-kB dysregulation in psoriatic disease.

rs2230926 (TNFAIP3 F127C missense) reduces A20 enzymatic activity directly; in combination with rs17728338 A allele, the combined deficit spans both A20 targeting (via reduced ABIN-1) and A20 function — a particularly high-risk configuration for NF-kB-driven skin and joint inflammation.

The IL-23A locus variant rs2066808 represents the parallel IL-23 pathway entry point into psoriatic inflammation. Both the NF-kB axis (TNIP1/TNFAIP3) and the IL-23/Th17 axis converge on the same keratinocyte activation endpoint; combined risk at both pathways likely amplifies plaque severity and treatment resistance.

Genotype Interpretations

What each possible genotype means for this variant.

GG Baseline ABIN-1 Function Normal

Two copies of the common G allele — typical NF-kB regulation and psoriasis risk

You carry two copies of the G reference allele, the common variant at rs17728338. Your TNIP1 expression is not reduced by this variant, and your ABIN-1 protein provides normal scaffolding support for A20-mediated NF-kB termination. Approximately 84% of people globally share this GG genotype (European frequency ~88%). Your psoriasis risk from this specific variant is at population baseline — about 2–3% lifetime prevalence in European populations from all contributing factors combined. This does not mean you carry zero autoimmune risk; other genetic and environmental factors independently determine your overall susceptibility.

AG Reduced ABIN-1 Scaffolding Intermediate

One A risk allele — modestly elevated psoriasis and psoriatic arthritis susceptibility

The additive effect of rs17728338 means each A allele independently reduces ABIN-1 scaffolding capacity for A20. As a heterozygote, one chromosome carries the normal G allele (maintaining TNIP1 expression) and one carries the A allele (reducing it). Net ABIN-1 levels are intermediate between GG and AA carriers.

The PsA-specific signal (P=2.20×10⁻⁸ in Chinese Han) exceeding the plaque psoriasis signal (P=1.21×10⁻⁴) suggests ABIN-1 deficiency may be particularly impactful in joint-resident immune cells. Carriers who develop psoriasis should be monitored for joint symptoms — early PsA is often missed and joint damage can be irreversible without prompt DMARD or biologic intervention.

AA Homozygous Risk — Reduced ABIN-1 High Risk

Two A risk alleles — substantially elevated psoriasis risk and markedly increased generalized pustular psoriasis susceptibility

GPP (generalized pustular psoriasis) differs fundamentally from plaque psoriasis in its severity and acuity. It presents as widespread sterile pustules across the body, accompanied by fever, malaise, and systemic inflammation. It can progress to multi-organ failure and has historically carried mortality risk without treatment. Biologic therapies (IL-17A inhibitors such as secukinumab, and the IL-36 receptor inhibitor spesolimab) are now effective first-line agents for GPP.

The biological reason for the dramatically elevated GPP risk in TNIP1 homozygotes relates to the loss of both copies of normal ABIN-1 scaffolding. In skin keratinocytes triggered by infection or inflammatory stimuli, A20 cannot be properly targeted without ABIN-1, and NF-kB remains constitutively active. This drives extreme IL-36γ and IL-1β production — the cytokines that define GPP pathophysiology — rather than the moderate TNF-α/IL-17 excess seen in plaque psoriasis.

Psoriatic arthritis risk is also substantially elevated; Yang et al. (PMID 23252691) found the TNIP1 locus was the strongest non-HLA PsA susceptibility signal in Chinese Han patients (P=2.20×10⁻⁸).